⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GRI News
GRI Bio, Inc. Common Stock
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
globenewswire.com
GRI
GRI Bio Announces Closing of $8.0 Million Public Offering
globenewswire.com
GRI
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
globenewswire.com
GRI
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
globenewswire.com
GRI